We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+41.13%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$354M
AUM Growth
–
Cap. Flow
+$291M
Cap. Flow %
82.33%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$90.6M
2
NSTG
NanoString Technologies, Inc.
NSTG
+$49M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$45.6M
4
AERI
Aerie Pharmaceuticals
AERI
+$45.2M
5
TLOG
TetraLogic Pharmaceuticals Corporation
TLOG
+$36.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$98.8M 27.92%
+3,054,744
New +$90.6M
NSTG
2
DELISTED
NanoString Technologies, Inc.
NSTG
$68.3M 19.29%
+3,959,440
New +$49M
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$62.3M 17.6%
+3,468,495
New +$45.2M
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$50M 14.12%
+2,579,062
New +$45.6M
TLOG
5
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$44.2M 12.5%
+4,644,705
New +$36.2M
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
$30.3M 8.56%
+1,101,234
New +$24.7M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Clarus Ventures, which disclosed 6 positions worth $354M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is IVERIC bio, Inc. Common Stock: 3,054,744 shares worth $98.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Clarus Ventures's largest Q4 2013 buy was IVERIC bio, Inc. Common Stock: 3,054,744 shares worth $98.8M.
  • Clarus Ventures's ten largest holdings make up 100% of its $354M portfolio in Q4 2013.
  • Clarus Ventures disclosed 6 positions in Q4 2013, its first 13F filing on record.

Based on Clarus Ventures's 13F filing for Q4 2013, filed 14 Feb 2014.